De Novo treatment of diffuse large B-cell lymphoma with Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in patients with cardiac comorbidity: A United Kingdom National Cancer Research Institute trial.
Fields, P Townsend, W Webb, A Counsell, N Pocock, C Smith, P Jack, A El-Mehidi, N Johnson, P Radford, John A
Fields, P
Townsend, W
Webb, A
Counsell, N
Pocock, C
Smith, P
Jack, A
El-Mehidi, N
Johnson, P
Radford, John A
Citations
Altmetric:
Abstract
The treatment of patients with diffuse large B-cell lymphoma (DLBCL) with cardiac comorbidity is problematic, because this group may not be able to receive anthracycline-containing chemoimmunotherapy. We designed a single-arm phase II multicenter trial of rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisolone (R-GCVP) in patients considered unfit for anthracycline-containing chemoimmunotherapy because of cardiac comorbidity.
Description
Date
2013-11-12
Publisher
Collections
Keywords
Type
Article
Citation
De Novo treatment of diffuse large B-cell lymphoma with Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in patients with cardiac comorbidity: A United Kingdom National Cancer Research Institute trial. 2013: J Clin Oncol